Skip to main content
. 2020 Jul 28;12(8):2097. doi: 10.3390/cancers12082097

Figure 1.

Figure 1

AhR-active compound screening. Wild-type 15-037 patient-derived Glioblastoma (GBM) cells (AhR+/+) or cells knockdown for the AhR by RNAi or CRISPR/Cas9 (AKO-19) were treated with DMSO (A), leflunomide (B), mexiletine (C), tranilast (D), β-naphthoflavone (BNF) (E), tryptamine (F), and omeprazole (OME) (G) in a spheroid invasion assay. Compound-induced invasion in wild-type and AhR knockdown cells were compared to solvent (DMSO) treated cells and indicated directly in each panel.